Spero Therapeutics Signs License Agreement With Everest Medicines To Develop, Manufacture And Commercialize SPR206 In Asia, With Option For SPR741 Rights, Initiates SPR206 Phase 1 Clinical Trial ; Co. To Receive $2M Upfront And Up To $59.5M In Milestones

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!